RU2674150C1 - Фармацевтическая комбинация - Google Patents

Фармацевтическая комбинация Download PDF

Info

Publication number
RU2674150C1
RU2674150C1 RU2014138166A RU2014138166A RU2674150C1 RU 2674150 C1 RU2674150 C1 RU 2674150C1 RU 2014138166 A RU2014138166 A RU 2014138166A RU 2014138166 A RU2014138166 A RU 2014138166A RU 2674150 C1 RU2674150 C1 RU 2674150C1
Authority
RU
Russia
Prior art keywords
pain
combination
acid
group
dimethylamino
Prior art date
Application number
RU2014138166A
Other languages
English (en)
Russian (ru)
Inventor
Петра Бломс-Функе
Клаус ШИНЕ
Томас КРИСТОФ
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2674150(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Application granted granted Critical
Publication of RU2674150C1 publication Critical patent/RU2674150C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2014138166A 2008-09-05 2009-09-04 Фармацевтическая комбинация RU2674150C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
EP08015625.0 2008-09-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011112444/15A Division RU2571501C2 (ru) 2008-09-05 2009-09-04 Фармацевтическая комбинация

Publications (1)

Publication Number Publication Date
RU2674150C1 true RU2674150C1 (ru) 2018-12-05

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014138166A RU2674150C1 (ru) 2008-09-05 2009-09-04 Фармацевтическая комбинация
RU2011112444/15A RU2571501C2 (ru) 2008-09-05 2009-09-04 Фармацевтическая комбинация

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011112444/15A RU2571501C2 (ru) 2008-09-05 2009-09-04 Фармацевтическая комбинация

Country Status (28)

Country Link
US (1) US20100063148A1 (https=)
EP (2) EP2735338B1 (https=)
JP (4) JP5731387B2 (https=)
KR (3) KR101730924B1 (https=)
CN (2) CN105520924B (https=)
AR (2) AR073361A1 (https=)
AU (3) AU2009289776A1 (https=)
BR (1) BRPI0920521A2 (https=)
CA (1) CA2735857C (https=)
CL (1) CL2011000317A1 (https=)
CO (1) CO6382142A2 (https=)
CY (2) CY1115751T1 (https=)
DK (2) DK2331210T3 (https=)
EC (1) ECSP11010869A (https=)
ES (2) ES2513394T3 (https=)
HR (2) HRP20140663T1 (https=)
HU (1) HUE043278T2 (https=)
IL (3) IL211135A (https=)
LT (1) LT2735338T (https=)
MX (1) MX2011002339A (https=)
PE (5) PE20142357A1 (https=)
PL (2) PL2331210T3 (https=)
PT (2) PT2331210E (https=)
RU (2) RU2674150C1 (https=)
SI (2) SI2331210T1 (https=)
TR (1) TR201904388T4 (https=)
WO (1) WO2010025931A2 (https=)
ZA (1) ZA201101449B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2007144195A2 (en) * 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
EP2992877A1 (en) * 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
ES2712072T3 (es) * 2011-07-20 2019-05-09 Torrent Pharmaceuticals Ltd Composición farmacéutica de tapentadol
EP3300726A1 (en) * 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
WO2014068372A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
ES3024232T3 (en) 2015-12-22 2025-06-04 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
SG11201900975XA (en) * 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PL213323B1 (pl) * 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie
ATE502629T1 (de) * 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
RS55769B1 (sr) * 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
The Textbook of Pharmaceutical Medicine, 5th, Blackwell Publishing Ltd, USA, 2006, P. 160. *
TZSCHENTKE T.M. et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties // The Journal of Pharmacology and Experimental Therapeutics. - 2007. - Vol. 323(1). - P. 265-276. *
TZSCHENTKE T.M. et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties // The Journal of Pharmacology and Experimental Therapeutics. - 2007. - Vol. 323(1). - P. 265-276. The Textbook of Pharmaceutical Medicine, 5th, Blackwell Publishing Ltd, USA, 2006, P. 160. *
Руководство по качеству лекарственных средств. Спецификации: контрольные испытания и критерии приемлемости. - Киев: Министерство здравоохранения Украины. 2004. С. 3. *
Руководство по качеству лекарственных средств. Спецификации: контрольные испытания и критерии приемлемости. - Киев: Министерство здравоохранения Украины. 2004. С. 3. ХОРУЖАЯ Т.Г. Биофармация - научное направление в разработке и совершенствовании лекарственных препаратов. - Томск: лаборатория оперативной полиграфии. 2006. С. 5-13. *
ХОРУЖАЯ Т.Г. Биофармация - научное направление в разработке и совершенствовании лекарственных препаратов. - Томск: лаборатория оперативной полиграфии. 2006. С. 5-13. *

Also Published As

Publication number Publication date
HRP20190500T1 (hr) 2019-08-09
US20100063148A1 (en) 2010-03-11
CL2011000317A1 (es) 2011-06-17
CN105520924A (zh) 2016-04-27
EP2735338A1 (en) 2014-05-28
TR201904388T4 (tr) 2019-05-21
HUE043278T2 (hu) 2019-08-28
BRPI0920521A2 (pt) 2018-01-16
ES2513394T3 (es) 2014-10-27
KR20160086981A (ko) 2016-07-20
KR20110057144A (ko) 2011-05-31
AR117613A2 (es) 2021-08-18
IL237392B (en) 2019-08-29
CY1121492T1 (el) 2020-05-29
WO2010025931A2 (en) 2010-03-11
HK1159011A1 (en) 2012-07-27
ECSP11010869A (es) 2011-04-29
AU2009289776A1 (en) 2010-03-11
JP2019131578A (ja) 2019-08-08
CY1115751T1 (el) 2017-01-25
PL2331210T3 (pl) 2014-12-31
JP2015096530A (ja) 2015-05-21
ES2719900T3 (es) 2019-07-16
RU2571501C2 (ru) 2015-12-20
PL2735338T3 (pl) 2019-07-31
AR073361A1 (es) 2010-11-03
JP5731387B2 (ja) 2015-06-10
JP2012501986A (ja) 2012-01-26
PT2331210E (pt) 2014-08-25
AU2018202879A1 (en) 2018-05-17
WO2010025931A3 (en) 2010-06-17
KR101730924B1 (ko) 2017-04-27
PE20142357A1 (es) 2015-02-04
DK2331210T3 (da) 2014-08-11
AU2018202879B2 (en) 2020-03-12
IL237392A0 (en) 2015-04-30
CN102159284B (zh) 2015-12-09
IL237391A (en) 2017-12-31
DK2735338T3 (en) 2019-04-23
CA2735857A1 (en) 2010-03-11
AU2016203053A1 (en) 2016-06-02
EP2331210B1 (en) 2014-07-09
CA2735857C (en) 2019-05-28
EP2331210A2 (en) 2011-06-15
MX2011002339A (es) 2011-04-04
PE20142371A1 (es) 2015-02-04
JP2017071636A (ja) 2017-04-13
IL237391A0 (en) 2015-04-30
IL211135A (en) 2017-09-28
EP2735338B1 (en) 2019-02-06
PT2735338T (pt) 2019-05-24
KR20170048602A (ko) 2017-05-08
PE20142372A1 (es) 2015-02-04
HK1198145A1 (en) 2015-03-13
IL211135A0 (en) 2011-04-28
ZA201101449B (en) 2011-10-26
CO6382142A2 (es) 2012-02-15
CN105520924B (zh) 2019-04-09
CN102159284A (zh) 2011-08-17
RU2011112444A (ru) 2012-10-10
KR101641519B1 (ko) 2016-07-21
PE20190914A1 (es) 2019-06-26
SI2331210T1 (sl) 2014-10-30
HRP20140663T1 (hr) 2014-10-10
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
SI2735338T1 (sl) 2019-04-30
AU2016203053B2 (en) 2018-01-25
PE20110291A1 (es) 2011-06-04

Similar Documents

Publication Publication Date Title
RU2674150C1 (ru) Фармацевтическая комбинация
US10206890B2 (en) Pharmaceutical combination
RU2675261C2 (ru) Фармацевтическая комбинация для лечения от боли
AU2007247481B2 (en) Pharmaceutical combination comprising 3- ( 3-Dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
US20110053914A1 (en) Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
DK2852384T3 (en) PHARMACEUTICAL COMPOSITION comprising (1R, 4R) -6'-FLUORO-N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXANE-1,1'-PYRANO [3,4 , B] INDOL] -4-AMINE AND AN ANTI-CONTRACTIVE AGENT
HK1159011B (en) Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
HK1198145B (en) Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and pregabalin or gabapentin